In plain English
Moderna Inc. develops biologic medicines, most notably its mRNA‑based therapies. The company’s latest focus is a personalized melanoma…
Company stock · NASDAQ · USD
MRNA
Moderna Inc
$200.10
Today
−$2.53-1.25%
vs yesterday’s close
Live price
- Opened at
- $196.69
- Day high
- $206.97
- Day low
- $183.00
- Yesterday’s close
- $202.63
- Sector
- Healthcare
- Industry
- Biotechnology
- Size
- Medium-sized company
- Market value
- $79.9 billion
- Number of shares
- 399.2 million
- Country
- US
- Went public
- Dec 7, 2018
- Exchange
- NASDAQ
- Website
- modernatx.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What MRNA is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Moderna Stock Slides Again Friday: What's Going On?
In brief
Moderna’s stock fell despite encouraging trial results, reflecting investor uncertainty about the vaccine’s broader impact and valuation.
Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%
In brief
Intismeran plus KEYTRUDA cuts melanoma recurrence or death risk by up to 58%, marking a major advance for personalized mRNA cancer therapy.
Why Is Moderna Stock Sinking Thursday?
In brief
Moderna’s shares plunged after a leaked Phase 3 result suggested a smaller benefit than earlier studies, sparking doubts about the vaccine’s added value.
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
In brief
Defensive stocks are gaining as investors retreat from tech and AI names amid inflation worries and a possible Fed rate hike.
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
In brief
NIH’s cancer vaccine initiative is boosting biotech stocks as investors bet on faster, mRNA‑based cancer therapies.
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
In brief
Tempus is deepening ties with Moderna and Merck on a personalized cancer vaccine, but the deal’s financial upside remains unclear, weighing on its stock price today.
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
In brief
Vaccine stocks are reacting to a Russian plague scare and company‑specific moves, with Moderna and Vaxcyte seeing modest gains and Novavax sliding slightly.
What's Going On With Moderna Stock on Wednesday?
In brief
Moderna’s stock dropped after announcing a new COO and mixed news on oncology and vaccine approvals, reflecting market caution on execution and timing.
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
In brief
AI‑driven tech gains hit a high, but higher Treasury yields and subscription‑cancellation worries temper the rally.
Why is Moderna (MRNA) Stock Trending After Hours?
In brief
Moderna’s stock surged after ESMO abstract acceptance, hinting at promising oncology data that could lift the company’s valuation.
Moderna Stock Is Surging: What's Going On?
In brief
Moderna’s melanoma trial success fuels a sharp rally, but analyst consensus remains cautious.
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
In brief
Moderna’s Phase 3 melanoma win validates its mRNA cancer platform, but the real test lies in scaling manufacturing, securing approvals, and expanding to other cancers.
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
In brief
Salazar’s August trades show an upbeat stance on Musk’s SpaceX, Buffett’s Berkshire, and biotech leaders, potentially guiding retail investors and adding pressure on those stocks.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
In brief
Positive Phase 3 results for a personalized mRNA cancer vaccine could ignite a new biotech boom beyond obesity drugs, boosting genomics and precision‑medicine ETFs.
Nvidia's Best Day Since April 2025, Cybersecurity Stocks Go Vertical: Stock Market Today
In brief
Nvidia’s upbeat revenue outlook and a surge in cybersecurity stocks lift tech, making the Nasdaq and tech ETFs the day’s leaders.
Moderna Borrows $2 Billion To Expand Oncology Business
In brief
Moderna’s $2 billion convertible note deal aims to fund oncology growth while managing dilution, but the market reacted negatively, pushing shares down.
Moderna Stock Edges Higher Tuesday: What's Happening?
In brief
Moderna’s stock gains are driven by a breakthrough melanoma trial and analyst upgrades that boost its oncology outlook.
What’s Going On With Tempus AI Stock on Monday?
In brief
TEM’s recent pullback reflects a re‑pricing of its momentum‑driven rally, with FDA clearance adding a new product but analyst sentiment remaining split.
Benzinga Bulls and Bears: Ross, Moderna, Webull
In brief
Ross and Webull’s Q2 beats lift guidance and confidence, while Moderna’s profit‑taking and Berkshire’s Alphabet stake shift focus toward tech and retail resilience amid higher yields.
MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
In brief
Retail hype turned corporate news into sharp price swings across biotech, retail, AI, and space stocks this week.
Bessent's Bond Band-Aid, Bitcoin's Best Week Since 2023: This Week on Wall Street
In brief
The Treasury’s buyback announcement briefly lowered long‑term yields, sparking a crypto rally, but the effect faded; Walmart’s earnings miss and Moderna’s breakthrough vaccine drove sharp moves in their respective stocks.
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
In brief
Moderna’s Phase 3 cancer vaccine win has revived the stock, underscoring the company’s shift from pandemic focus to broader mRNA therapeutics.
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
In brief
Moderna’s Phase 3 melanoma win could be the catalyst that turns its mRNA platform into a sustainable oncology business, redefining its future beyond COVID‑19.
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
In brief
Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for MRNA will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.